Evidence map›Paper›PMID 36167373›Full record

ArticleBMJ open2022

Economic evaluation of endovascular treatment for acute ischaemic stroke in Thailand.

Waranya Rattanavipapong, Thanaboon Worakijthamrongchai, Budsadee Soboon, Vilawan Luankongsomchit, Mananchaya Kongmuangpuk, Wanrudee Isaranuwatchai, Yot Teerawattananon, Yongchai Nilanont

Abstract read
In one paragraph

Article in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Waranya RattanavipapongHealth Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Nonthaburi, Thailand.ORCID 0000-0001-8628-2149
Thanaboon WorakijthamrongchaiDepartment of Neurology, Neurological Institute of Thailand, Bangkok, Thailand.
Budsadee SoboonHealth Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Nonthaburi, Thailand.
Vilawan LuankongsomchitHealth Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Nonthaburi, Thailand.
Mananchaya KongmuangpukSiriraj Stroke Center, Siriraj hospital, Bangkok, Thailand.
Wanrudee IsaranuwatchaiHealth Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Nonthaburi, Thailand.
Yot TeerawattananonHealth Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Nonthaburi, Thailand yot.t@hitap.net.ORCID 0000-0003-2217-2930
Yongchai NilanontSiriraj Stroke Center, Siriraj hospital, Bangkok, Thailand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesEndovascular therapy (EVT) has proven to be clinically effective in treating large vessel occlusion acute ischaemic stroke (AIS), either alone or in combination with intravenous alteplase. Despite this, there is a limited evidence on the cost-effectiveness of EVT in Thailand and other low-income and middle-income countries. This study aims to assess whether EVT is a cost-effective therapy for AIS, and to estimate the fiscal burden to the Thai government through budget impact analysis.

methodsAn economic evaluation was performed to compare AIS therapy with and without EVT from a societal perspective. The primary outcome was incremental cost-effectiveness per quality-adjusted life year (QALY) gained. Clinical parameters were derived from both national and international literature, while cost and utility data were collected locally. The analysis applied a cost-effectiveness threshold of 160 000 Baht (~$5000) per QALY, as set by the Thai government.

resultsBoth EVT alone and EVT combined with intravenous alteplase, among patients who are ineligible and eligible for intravenous alteplase, respectively, improved health outcomes but incurred additional cost. The combination of EVT and intravenous alteplase was associated with an incremental cost-effectiveness ratio (ICER) of 146 800 THB per QALY gained compared with intravenous alteplase alone, and the ICER of EVT alone compared with supportive care among patients ineligible for intravenous alteplase was estimated at 115 000 THB per QALY gained. Sensitivity analysis showed that the price of EVT has the greatest impact on model outcomes. Over a time horizon of 5 years, the introduction of EVT into the Thai health benefit package would require an additional budget of 887 million THB, assuming 2000 new cases per year.

conclusionsEVT represents good value for money in the Thai context, both when provided to patients eligible for intravenous alteplase, and when provided alone to those who are ineligible for intravenous alteplase.

Indexed as

Brain IschemiaIschemic StrokeStrokeCost-Benefit AnalysisHumansQuality-Adjusted Life YearsThailandTissue Plasminogen ActivatorTissue Plasminogen ActivatorHealth economicsHealth policyRationingStroke

Identifiers

PMID36167373
PMCPMC9516067

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.